May 28, 2025
Click here to view this announcement as a PDF.
• Read MoreMay 27, 2025
Click here to view this announcement as a PDF.
• Read MoreMay 21, 2025
Click here to view this announcement as a PDF.
• Read MoreMay 21, 2025
Click here to view this announcement as a PDF.
• Read MoreMay 20, 2025
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at the Special Meeting held earlier today, both resolutions put to Stockholders were duly passed. The proxy votes cast in respect of the Resolutions are as follows: No. Summary of Resolution For* % Against % Withheld** 1 To authorise, in […]
• Read MoreMay 19, 2025
1. Issuer Details ISIN USU5500L1045 Issuer Name LungLife AI, Inc. UK or Non-UK Issuer Non-UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Cable Car Capital LLC City of registered office (if applicable) San Francisco Country of registered office (if applicable) United […]
• Read MoreApril 29, 2025
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that, further to its previous announcements, the Company will shortly send a circular to Stockholders (the "Circular"), which contains a notice of Special Meeting of Stockholders (the “Special Meeting”) and resolutions (the “Resolutions”) in connection with the proposed cancellation of admission […]
• Read MoreApril 17, 2025
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that it has entered into a conditional exclusive license and distribution agreement (the “Agreement”) for the commercial distribution of its LungLB® test (the “LungLB® test”) in the US with Circulogene Theranostics, Inc. a US liquid biopsy diagnostics company (“Circulogene” or the […]
• Read MoreFebruary 4, 2025
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, provides the following update. As set out in the Operational Update on 19 November 2024, the Company had been actively engaged in discussions with several potential strategic partners. These discussions were aimed at identifying a partner that not only shares the Company’s […]
• Read MoreNovember 19, 2024
Strong progress towards commercialisation of LungLB® LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, provides an update on its operational progress made since the release of its interim results announcement. The Company has continued to execute on the commercial proof of concept of LungLB® and to explore opportunities for a suitable […]
• Read More
LungLife AI licensure/accreditation information posted here.